Vanguard reports 13.49% (9,704,948 shares) in West Pharma

West Pharmaceutical Services (WST): Schedule 13G/A filed by The Vanguard Group The Vanguard Group reported beneficial ownership of 9,704,948 shares of WST common stock, representing 13.49% of the class as of 09/30/2025.

Rhea-AI Filing Summary

West Pharmaceutical Services (WST): Schedule 13G/A filed by The Vanguard Group

The Vanguard Group reported beneficial ownership of 9,704,948 shares of WST common stock, representing 13.49% of the class as of 09/30/2025. Vanguard reported 0 shares with sole voting power and 422,261 with shared voting power. It reported 9,018,715 shares with sole dispositive power and 686,233 with shared dispositive power.

Vanguard states the securities are held in the ordinary course and not to influence control. Its clients have the right to receive dividends or sale proceeds, and no single client’s interest exceeds 5%.

FAQ

What stake in WST did The Vanguard Group report?

The Vanguard Group reported beneficial ownership of 13.49% of West Pharmaceutical Services common stock.

How many WST shares does The Vanguard Group beneficially own?

Vanguard reported 9,704,948 shares beneficially owned as of 09/30/2025.

What voting power did The Vanguard Group report for WST?

Vanguard reported 0 shares with sole voting power and 422,261 shares with shared voting power.

What dispositive power did The Vanguard Group report for WST?

Vanguard reported 9,018,715 shares with sole dispositive power and 686,233 shares with shared dispositive power.

Is The Vanguard Group filing passive for WST?

Yes. Vanguard certified the holdings were acquired and are held in the ordinary course and not to change or influence control.

Do any Vanguard clients hold more than 5% of WST?

No. Vanguard states no one other person's interest exceeds 5%.

What is the event date for this ownership report?

The date of the event is 09/30/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/31/2025 - 11:41 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 15)

West Pharmaceutical Services Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

955306105

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 955306105

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 422,261.00
7	Sole Dispositive Power 9,018,715.00
8	Shared Dispositive Power 686,233.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,704,948.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.49 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: West Pharmaceutical Services Inc
(b)	Address of issuer's principal executive offices: 530 Herman O West Dr, Exton, PA, 19341
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 955306105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 9704948
(b)	Percent of class: 13.49 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 422261
	(iii) Sole power to dispose or to direct the disposition of: 9018715
	(iv) Shared power to dispose or to direct the disposition of: 686233
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	10/31/2025